Century Therapeutics, Inc. (IPSC)
2.10
-0.01
(-0.47%)
USD |
NASDAQ |
Sep 03, 13:40
Century Therapeutics Research and Development Expense (TTM) : 66.62M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 66.62M |
| March 31, 2026 | 73.30M |
| December 31, 2025 | 82.56M |
| September 30, 2025 | 92.47M |
| June 30, 2025 | 97.00M |
| March 31, 2025 | 97.10M |
| December 31, 2024 | 93.94M |
| September 30, 2024 | 90.18M |
| June 30, 2024 | 89.04M |
| March 31, 2024 | 88.01M |
| December 31, 2023 | 92.71M |
| September 30, 2023 | 96.00M |
| Date | Value |
|---|---|
| June 30, 2023 | 99.11M |
| March 31, 2023 | 100.88M |
| December 31, 2022 | 97.17M |
| September 30, 2022 | 93.38M |
| June 30, 2022 | 87.03M |
| March 31, 2022 | 81.47M |
| December 31, 2021 | 75.65M |
| September 30, 2021 | 66.29M |
| June 30, 2021 | 57.56M |
| March 31, 2021 | 47.11M |
| December 31, 2020 | 39.68M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Tenax Therapeutics, Inc. | 45.26M |
| Manhattan Scientifics, Inc. | -- |
| Exicure, Inc. | 2.029M |
| Absci Corp. | 86.49M |
| Celularity, Inc. | 9.222M |